1. Home
  2. ORN vs CTNM Comparison

ORN vs CTNM Comparison

Compare ORN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Group Holdings Inc.

ORN

Orion Group Holdings Inc.

SELL

Current Price

$7.44

Market Cap

542.0M

Sector

Industrials

ML Signal

SELL

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

SELL

Current Price

$9.66

Market Cap

550.7M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
ORN
CTNM
Founded
1994
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
542.0M
550.7M
IPO Year
2007
2024

Fundamental Metrics

Financial Performance
Metric
ORN
CTNM
Price
$7.44
$9.66
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$14.65
★ $21.43
AVG Volume (30 Days)
591.7K
★ 596.9K
Earning Date
10-27-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 220.00
0.46
EPS
★ 0.15
N/A
Revenue
★ $852,260,000.00
N/A
Revenue This Year
$10.18
N/A
Revenue Next Year
$6.44
N/A
P/E Ratio
$50.50
★ N/A
Revenue Growth
★ 7.01
N/A
52 Week Low
$6.75
$6.73
52 Week High
$17.40
$17.79

Technical Indicators

Market Signals
Indicator
ORN
CTNM
Relative Strength Index (RSI) 40.52 46.25
Support Level $6.75 $8.59
Resistance Level $9.78 $13.72
Average True Range (ATR) 0.67 0.77
MACD -0.05 0.23
Stochastic Oscillator 20.87 42.33

Price Performance

Historical Comparison
ORN
CTNM

About ORN Orion Group Holdings Inc.

Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: